Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Preclinical Comparison of [In]In- and [Ac]Ac-DOTA-Trastuzumab IgG, F(ab') and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer.
Mol Pharm
January 2025
Department of Pharmaceutical Sciences, University of Toronto, Toronto, ON M5S 3M2, Canada.
Radioimmunotherapy (RIT) with α-particle-emitting, Ac complexed to trastuzumab may offer an alternative treatment for patients who progress on HER2-targeted therapies. Moreover, RIT with [Ac]Ac-DOTA-trastuzumab could be combined with SPECT/CT imaging with [In]In-DOTA-trastuzumab in a theranostic approach. In this study, we compared DOTA-conjugated trastuzumab IgG, F(ab') or Fab complexed to In or Ac for SPECT/CT imaging and α-particle RIT of subcutaneous (s.
View Article and Find Full Text PDFEfficient bone marrow irradiation and low uptake by non-haematological organs with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell transplantation.
Bone Marrow Transplant
September 2024
School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
We report the results of a Phase I radiation dose escalation study using an yttrium-90 (Y) labelled anti-CD66 monoclonal antibody given with standard conditioning regimen for patients receiving haematopoietic stem cell transplants for myeloid leukaemia or myeloma. The Y-labelled anti-CD66 was infused prior to standard conditioning. In total, 30 patients entered the trial and 29 received Y-labelled mAb, at infused radiation activity levels of 5, 10, 25, or 37.
View Article and Find Full Text PDFPanitumumab-DOTA-In: An Epidermal Growth Factor Receptor Targeted Theranostic for SPECT/CT Imaging and Meitner-Auger Electron Radioimmunotherapy of Triple-Negative Breast Cancer.
Mol Pharm
October 2022
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
Epidermal growth factor receptors (EGFR) are overexpressed in triple-negative breast cancer (TNBC) and are an attractive target for the development of theranostic radiopharmaceuticals. We studied anti-EGFR panitumumab labeled with In (panitumumab-DOTA-In) for SPECT/CT imaging and Meitner-Auger electron (MAE) radioimmunotherapy (RIT) of TNBC. Panitumumab-DOTA-In was bound, internalized, and routed to the nucleus in MCF7, MDA-MB-231/Luc, and MDA-MB-468 human breast cancer (BC) cells dependent on the EGFR expression level (1.
View Article and Find Full Text PDFPreparation and preclinical characterization of In-DTPA-Anti-MUC1 as a radioimmunoconjugate for diagnosis of breast cancer by single-photon emission computed tomography.
J Cancer Res Ther
April 2022
Department of Waste Management, Materials and Fuel Cycle Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
Context: Targeting MUC1 antigens which are overexpressed in 80% of breast cancers can be widely used in the field of radioimmunoscintigraphy (RIS) of breast cancer.
Aims: The aim of this study was to develop a new diagnostic labeled compound for breast cancer RIS.
Settings And Design: In this study, an efficient indirect labeling method of PR81 with Indium-111 was developed and preliminary preclinical qualifications were reported.
Pulmonary translocation of ultrafine carbon particles in COPD and IPF patients.
Inhal Toxicol
May 2022
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Objective: Epidemiological studies indicate association between elevated air pollution and adverse health effects. Several mechanisms have been suggested, including translocation of inhaled ultrafine carbon (UFC) particles into the bloodstream. Previous studies in healthy subjects have shown no significant pulmonary translocation of UFC-particles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!